Recent research identified some biomarkers and indicators that improve the prediction of immunotherapy responses, complementing traditional markers like programmed death-ligand 1 (PD-L1), the tumor mutational burden (TMB), and microsatellite instability (MSI). Here, CD274 is linked to neoplasm.